The PD0325901 used in 2i, and many other Mek inhibitors, do not disrupt the phosphorylation of the Mek1/2 activation loop, which can explain the rebound in phosphorylated Erk1/2 and pathway output that is observed with this type of inhibitors, notably in Ras-driven cancers. Here, MAPK3 is linked to cancer.